Fatimah I. Alruwaii

Fatimah I. Alruwaii

Auto-generated profile, based on publicly available information

Fatimah I. Alruwaii

Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, MI, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Human Pathology
Verified
Journal Article
Closed access
KAKhaleel I. Al-Obaidy
Khaleel I. Al-Obaidy
FAFatimah I. Alruwaii
Fatimah I. Alruwaii
TUThomas M. Ulbright
Thomas M. Ulbright
MIMuhammad T. Idrees
Muhammad T. Idrees

25 November 2019 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
FAFatimah Alruwaii
Fatimah Alruwaii
JHJen-Fan Hang
Jen-Fan Hang
BZBao‐Rung Zeng
Bao‐Rung Zeng
HCHarvey M. Cramer
Harvey M. Cramer
CLChiung‐Ru Lai
Chiung‐Ru Lai
HWHoward H. Wu
Howard H. Wu

1 July 2021 in Diagnostic Cytopathology
Verified
Journal Article
Closed access
PDF file
CSCarlo De la Sancha
Carlo De la Sancha
SKShahbaz Khan
Shahbaz Khan
FAFatimah Alruwaii
Fatimah Alruwaii
HCHarvey Cramer
Harvey Cramer
RSRomil Saxena
Romil Saxena

4 February 2024 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
EBEjas Palathingal Bava
Ejas Palathingal Bava
NGNilesh Gupta
Nilesh Gupta
FAFatimah I. Alruwaii
Fatimah I. Alruwaii
RNRyan Nelson
Ryan Nelson
KAKhaleel I. Al-Obaidy
Khaleel I. Al-Obaidy
Renal cell carcinoma with fibromyomatous stroma, recognized as a provisional entity in the current 2022 World Health Organization classification of renal neoplasms, is rare. Recent evidence suggests recurrent alterations in the mTOR pathway, supporting its recognition as a distinct entity. Herein, we report 2 renal cell carcinomas with fibromyomatous stroma with MTOR mutations occurring in 62- and 72-year-old women and review the literature to support its recognition as a distinct entity, focusing on the characteristic morphology, immunohistochemical staining patterns as well as genetic alterations.

4 May 2020 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
PDF file
FAFatimah I. Alruwaii
Fatimah I. Alruwaii
MIMuhammad Idrees
Muhammad Idrees
OSOmer Saeed
Omer Saeed
SCShaoxiong Chen
Shaoxiong Chen
Context. Primary renal mesenchymal neoplasms are rare but diverse. Several neoplasms of mesenchymal derivation can arise as a primary renal mass; however, incidental tumors are identified in nephrectomies performed for end-stage renal disease or other malignant epithelial renal neoplasms. In this article, we document their frequencies with demographic information in nephrectomy specimens. Design. We retrospectively searched our database for nephrectomy specimens from the year 2000 to 2016. Results. A total of 224 cases were identified with an incidence rate of 4.4% (224/5128). One hundred ninety (85%) neoplasms were benign, 27 (12%) were malignant, and 7 (3%) were of intermediate biologic behavior. The majority of cases occurred in adults (93%, 208/224), and 39% of cases represented an incidental finding. The most common neoplasms were angiomyolipoma (58%) and renomedullary interstitial cell tumor (17%). Malignant mesenchymal kidney tumors are rare (0.39% of nephrectomy specimens). The most common adults’ malignant tumors in our survey were synovial sarcoma and Ewing’s sarcoma. Conclusion. Primary renal mesenchymal tumors are rare and are mostly benign in nature with many incidentally identified lesions. They arise in different age groups with malignant lesions usually presenting at a younger mean age.

24 March 2020 in Human Pathology
Verified
Journal Article
Closed access
FAFatimah Alruwaii
Fatimah Alruwaii
DGDavid J. Grignon
David J. Grignon
MIMuhammad T. Idrees
Muhammad T. Idrees